Listed

Lineage Cell Therapeutics, Inc.: Form 10-Q for the period ended Jun 30, 2023

Filed with the SEC on Aug 10, 2023 and accepted by EDGAR at Aug 10, 2023, 16:16 ET.

Share

Management's discussion and analysis

As filed, 32,560 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

The following discussion and analysis of financial condition and results of operations should be read in conjunction with our unaudited condensed consolidated interim financial statements and notes thereto included in this report and our audited financial statements and notes thereto for the year ended December 31, 2022 included in the 2022 10-K. Past operating results are not necessarily indicative of results that may occur in future periods.

The following discussion includes forward-looking statements. See “Special Note Regarding Forward-Looking Statements,” above. Forward-looking statements are not guarantees of future performance and our actual results may differ materially from those currently anticipated and from historical results depending upon a variety of factors, including, but not limited to, those discussed in Part I, Item 1A. Risk Factors of our 2022 10-K, and in our subsequent filings with the SEC, including any discussed in Part II, Item 1A of this report under the heading “Risk Factors.”

All information presented in this report is based on our fiscal year. Unless otherwise stated, references to particular years, quarters, months or periods refer to our fiscal years ending December 31 and the associated quarters, months and periods of those fiscal years.

Company and Business Overview

We are a clinical-stage biotechnology company developing novel allogeneic cell therapies to address unmet medical needs. Our programs are based on our proprietary cell-based technology platform and associated development and manufacturing capabilities. From this platform, we design, develop, manufacture, and test specialized human cells with anatomical and physiological functions similar or identical to cells found naturally in the human body. The cells we manufacture are created by applying developmental biological differentiation protocols to established, well-characterized, and self-renewing pluripotent cell lines. These cells are transplanted into patients and are designed to (a) replace or support cells that are absent or dysfunctional due to degenerative disease, aging, or traumatic injury, and (b) restore or augment the patient’s functional activity.

Our strategy is to efficiently leverage our technology platform and our development, formulation, delivery, and manufacturing capabilities to advance our programs internally or in conjunction with strategic partners to further enhance their value and probability of success. As one example, in December 2021 we entered into a Collaboration and License Agreement (the “Roche Agreement”) with F. Hoffmann-La Roche Ltd and Genentech, Inc., a member of the Roche Group (collectively or individually, “Roche” or “Genentech”), wherein we granted to Roche exclusive worldwide rights to develop and commercialize retinal pigment epithelium (“RPE”) cell therapies, including our proprietary cell therapy program known as OpRegen®, for the treatment of ocular disorders, including geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Under the terms of the Roche Agreement, Lineage received a $50.0 million upfront payment and is eligible to receive up to $620.0 million in certain developmental, regulatory, and commercialization milestone payments. Lineage also is eligible to receive tiered double-digit percentage royalties on net sales of OpRegen in the U.S. and other major markets. See Note 14 (Commitments and Contingencies) for additional information regarding the Roche Agreement.

As of June 30, 2023, we have five allogeneic, or “off-the-shelf,” cell therapy programs in development, of which three have reached human clinical testing:

Product Candidates

  • OpRegen®, an allogeneic RPE cell replacement therapy currently in a Phase 2a multicenter clinical trial, being conducted by Roche, for the treatment of GA secondary to AMD, also known as atrophic or dry AMD. A previous Phase 1/2a trial we conducted enrolled individuals with dry AMD with GA. In December 2021, this program was partnered with Roche for further clinical development and commercialization.
  • OPC1, an allogeneic oligodendrocyte progenitor cell therapy currently in long-term follow-up from a Phase 1/2a multicenter clinical trial for cervical spinal cord injuries (“SCI”). To date, five patients with thoracic spinal cord injuries and 25 patients with cervical SCI have been enrolled in clinical trials of OPC1. We recently received a response from the U.S. Food and Drug Administration to our Type B meeting submission which will help guide our next regulatory interactions. The clinical development of OPC1 has been partially funded by $14.3 million received under a grant from the California Institute for Regenerative Medicine (“CIRM”). Additional clinical trials are being planned.

27 | Page

  • ANP1, an allogeneic auditory neuron progenitor cell transplant currently in preclinical development for the treatment of debilitating hearing loss (“DHL”).
  • PNC1, an allogeneic photoreceptor cell transplant currently in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage.
  • VAC, an allogeneic cancer immunotherapy comprised of antigen-presenting dendritic cells. A Phase 1 clinical trial in non-small cell lung cancer (“NSCLC”) of one of the VAC product candidates, VAC2, was recently completed. This clinical trial was funded and conducted by Cancer Research UK (“CRUK”), one of the world’s largest independent cancer research charities. Another VAC-based product candidate is in preclinical development with our partner, Immunomic Therapeutics, Inc. (“ITI”), for the treatment of glioblastoma multiforme (“GBM”).

Other Programs

We have additional undisclosed product candidates being considered for development covering a range of therapeutic areas and unmet medical needs. Generally, these product candidates are based on the same platform technology and employ a similar guided cell differentiation and transplant approach as the product candidates described above, but in some cases may also include genetic modifications designed to enhance efficacy and/or safety profiles.

In addition to seeking to create value for shareholders by developing product candidates and advancing those candidates through clinical development, we also may seek to create value from our intellectual property and additional related technologies and capabilities, through partnering and/or strategic transactions.

Critical Accounting Estimates

An accounting policy is deemed critical if it requires an accounting estimate to be made based on assumptions about matters that are highly uncertain at the time the estimate is made, if different estimates reasonably could have been used, or if changes in the estimate that are reasonably likely to occur could materially impact the financial statements. See Part II, Item 7 – Critical Accounting Estimates and our consolidated financial statements and related notes in Part II, Item 8 of our 2022 10-K for accounting policies and related estimates we believe are the most critical to understanding our condensed consolidated interim financial statements, financial condition and results of operations and which require complex management judgment and assumptions or involve uncertainties. There have not been any changes to our significant accounting policies or their application since we filed our 2022 10-K.

Results of Operations

Comparison of Three and Six Months Ended June 30, 2023 and 2022

Revenues and Cost of Sales

The amounts in the table below show our consolidated revenues, by source, and cost of sales for the periods presented (in thousands).

Three Months ended June 30, (unaudited) 2023 2022 $ change % change
Collaboration revenues $2,871 $4,148 $(1,277) (31)%
Royalties and license fees 354 405 (51) (13)%
Total revenues 3,225 4,553 (1,328) (29)%
Cost of sales (127) (215) 88 (41)%
Gross profit $3,098 $4,338 $(1,240) (29)%

28 | Page

Six Months ended June 30, (unaudited) 2023 2022 $ change % change
Collaboration revenues $4,992 $9,013 $(4,021) (45)%
Royalties and license fees 619 777 (158) (20)%
Total revenues 5,611 9,790 (4,179) (43)%
Cost of sales (246) (391) 145 (37)%
Gross profit $5,365 $9,399 $(4,034) (43)%

For the three months ended June 30, 2023, the $1.3 million decrease in total revenues was due to a $1.3 million decrease in collaboration revenues related to less current period recognition of the $50.0 million upfront licensing payment from Roche, resulting from an updated collaboration forecast. The collaboration revenue was included in deferred revenues at December 31, 2022 (see Note 3 for further discussion).

For the six months ended June 30, 2023, the $4.2 million decrease in total revenues was primarily due to a $4.0 million decrease in collaboration revenues related to less current period recognition of the $50.0 million upfront licensing payment from Roche, resulting from an updated collaboration forecast. The collaboration revenue was included in deferred revenues at December 31, 2022 (see Note 3 for further discussion).

Operating expenses

Our operating expenses consist of research and development expenses and general and administrative expenses.

Research and development expenses. These expenses consist of costs incurred for company-sponsored, collaborative and contracted research and development activities. These costs include direct expenses and indirect research-related overhead expenses including compensation and related benefits, stock-based compensation, consulting fees, research and laboratory fees, rent of research facilities, amortization of intangible assets, and license fees paid to third parties to acquire patents or licenses to use patents and other technology. Research and development expenses that have an alternative future use will be capitalized as tangible assets, and costs with no future benefit or alternative use will be expensed as incurred. Research and development expenses incurred and reimbursed by grants from third parties approximate the grant income recognized in our consolidated statements of operations. Royalties and sublicensing fees are recorded as research and development expenses, unless they are associated with royalties from product sales, which we classify as cost of sales in our consolidated statements of operations. We expect our total research and development expenses to fluctuate each reporting period based on several factors including (i) the stage of development for each cell therapy program, (ii) the availability of resources to work on each program, and (iii) the timing of contractual obligations.

General and administrative expenses. These expenses include employee and director compensation and related benefits, including stock-based compensation, for executive and corporate personnel, professional and consulting fees, and allocated overhead such as facilities rent and equipment rent and maintenance, insurance costs allocated to general and administrative expenses, costs of patent applications, prosecution and maintenance, stock exchange-related costs, depreciation expense, marketing costs, legal and accounting costs, and other miscellaneous.

The amounts in the table below are our consolidated operating expenses for the periods presented (in thousands).

Three Months ended June 30, (unaudited) 2023 2022 $ change % change
Research and development $3,873 $3,302 $571 17%
General and administrative 4,249 5,270 (1,021) (19)%
Total $8,122 $8,572 $(450) (5)%

29 | Page

Six Months ended June 30, (unaudited) 2023 2022 $ change % change
Research and development $8,058 $6,290 $1,768 28%
General and administrative 8,973 13,739 (4,766) (35)%
Total $17,031 $20,029 $(2,998) (15)%

The following table shows the amount of our total research and development expenses by program for the periods presented (in thousands).

Three Months ended June 30, (unaudited) Amount 2023 2022 Percent of Total 2023 2022
OpRegen® $1,580 $1,137 41% 34%
OPC1 1,432 1,139 36% 35%
ANP1 697 173 18% 5%
PNC1 75 130 2% 4%
VAC platform 20 703 1% 21%
All other programs 69 20 2% 1%
Total research and development expenses $3,873 $3,302 100% 100%
Six Months ended June 30, (unaudited) Amount 2023 2022 Percent of Total 2023 2022
OpRegen® $3,100 $2,290 38% 36%
OPC1 2,833 2,065 35% 33%
ANP1 1,140 235 14% 4%
PNC1 233 245 3% 4%
VAC platform 306 1,430 4% 23%
All other programs 446 25 6% 0%
Total research and development expenses $8,058 $6,290 100% 100%

Research and development expenses. For the three months ended June 30, 2023, the $0.6 million increase in total research and development expenses is mainly attributable to: (i) a $0.4 million net increase in expenses related to our OpRegen program; (ii) a $0.3 million net increase in expenses related to our OPC1 program, primarily related to nonclinical activities; (iii) a $0.5 million increase in expenses related to our ANP1 program, primarily related to nonclinical development activities. These increases were partially offset by a $0.7 million decrease in expense related to our VAC program, primarily related to reduced manufacturing activities.

For the six months ended June 30, 2023, the $1.8 million increase in total research and development expenses is mainly attributable to: (i) a $0.8 million net increase in expenses related to our OpRegen program, which includes the work being performed on the Roche collaboration; (ii) a $0.8 million net increase in expenses related to our OPC1 program, primarily related to nonclinical activities; (iii) a $0.9 million increase in expenses related to our ANP1 program, primarily related to nonclinical development activities; and (iv) a $0.4 million increase in expenses related to other programs. These increases were partially offset by a $1.1 million decrease in expense related to our VAC program, primarily related to reduced manufacturing activities.

30 | Page

General and administrative expenses. For the three months ended June 30, 2023, the $1.0 million year-over-year decrease in general and administrative expenses was primarily attributable to (i) a $0.5 million decrease in legal and litigation expense, primarily related to the Asterias litigation settlement, and an (ii) overall reduction in costs incurred for services provided by third parties, consulting costs and stock-based compensation expense.

For the six months ended June 30, 2023, the $4.8 million year-over-year decrease in general and administrative expenses was primarily attributable to (i) a $4.0 million decrease in legal and litigation expense, primarily related to the Asterias litigation settlement, and an (ii) overall reduction in costs incurred for services provided by third parties, consulting costs and stock-based compensation expense.

Other income and (expenses), net

The following table shows the amount of other income and (expense), net, for the periods presented (in thousands):

Other income (expenses), net Three Months ended June 30, (unaudited) 2023 2022 $ change % change
Interest income, net $382 $51 $331 649%
Unrealized loss on marketable equity securities, net (150) (709) 559 (79)%
Gain on revaluation of warrant liability - 2 (2) (100)%
Other expenses, net (411) (1,892) 1,481 (78)%
Total $(179) $(2,548) $2,369 (93)%
Other income (expenses), net Six Months ended June 30, (unaudited) 2023 2022 $ change % change
Interest income, net $792 $51 $741 1453%
Unrealized loss on marketable equity securities, net (110) (1,444) 1,334 (92)%
Gain on revaluation of warrant liability 1 223 (222) (100)%
Other expenses, net (427) (2,075) 1,648 (79)%
Total $256 $(3,245) $3,501 (108)%

Interest income, net. During the third quarter of 2022, we began to invest our excess cash in short-term U.S. Treasury securities resulting in an increase in interest income. See Note 4 (Marketable Debt Securities) to our condensed consolidated interim financial statements included in this report for additional information regarding our marketable debt securities.

Unrealized loss on marketable equity securities, net. We expect our total other income (expenses), net, to fluctuate each reporting period based on the changes in the market price of the common stock of OncoCyte Corporation (“OncoCyte”), which could impact our net income or loss reported in our condensed consolidated statements of operations for a particular reporting period. We also account for the shares we hold in HBL as marketable equity securities. These shares are carried at fair market value on our consolidated balance sheets. The accounting transactions for these shares were not material for either of the three and six months ended June 30, 2023. The accounting transactions for these shares were $0.7 million and $1.4 million for the three and six months ended June 30, 2022. See Note 5 (Marketable Equity Securities) to our condensed consolidated interim financial statements included in this report for additional information regarding our marketable equity securities.

Other expenses, net. Other expenses, net, for each of the three and six months ended June 30, 2023 and 2022 consisted of net foreign currency transaction gains and losses recognized by our subsidiaries Cell Cure and ES Cell International Pte. Ltd and an employee retention credit payroll tax refund (discussed below). Foreign currency transaction gains and losses for the periods presented are principally related to the remeasurement of the U.S. dollar denominated notes payable and notes receivable between Cell Cure and Lineage.

31 | Page

Under the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”), the Company is eligible for an employee retention credit subject to certain criteria. The employee retention credit is a payroll tax refund per employee, which was designed by the U.S. Treasury Department to assist businesses that retained employees during the COVID pandemic. For the six months ended June 30, 2023, we recorded an employee retention credit of $0.5 million, due to a decline in the quarterly revenue during 2020 and 2021 as compared to the same quarterly period in 2019. We recorded the transaction within other expenses, net on the condensed consolidated statement of operations and as a receivable within prepaid expenses and other current assets on the condensed consolidated balance sheet. We accounted for the employee retention credit by analogy to International Accounting Standards (IAS) 20, Accounting for Government Grants and Disclosure of Government Assistance, of International Financial Reporting Standards (IFRS).

Income Taxes

Under ASC 740, Income Taxes, a valuation allowance is provided when it is more likely than not that some portion of the deferred tax assets will not be realized. We established a full valuation allowance as of December 31, 2018, due to the uncertainty of realizing future tax benefits from the net operating loss carryforwards and other deferred tax assets, including foreign net operating losses generated by its subsidiaries.

For the six months ended June 30, 2023, Lineage recorded a $1.8 million deferred tax benefit due to the ability to offset certain deferred tax assets against the deferred tax liability associated with IPR&D, and the related release of the valuation allowance. It was determined that a portion of the deferred tax liability related to the indefinite lived assets may be realized prior to the expiration of certain pre 2018 net operating losses. Lineage did not record a deferred tax benefit for the three months ended June 30, 2023, and did not record a deferred tax benefit for the three and six months ended June 30, 2022. See Note 13 (Income Taxes) to our condensed consolidated interim financial statements included in this report for additional information.

Liquidity and Capital Resources

Sources of Liquidity

We have historically funded our operations primarily through proceeds from the sale of shares of our common stock, the sale of common stock of our former subsidiaries, research grants, revenues from collaborations, and royalties from product sales that are unrelated to our current cell therapy product candidates.

As of June 30, 2023, $58.0 million remained available for sale under our at the market offering program and we owned marketable securities with a fair value of $12.0 million based on the closing price of such securities on that date. See Note 4 (Marketable Debt Securities), Note 5 (Marketable Equity Securities) and Note 11 (Shareholders’ Equity) to our condensed consolidated interim financial statements included in this report for additional information regarding the marketable securities we own and our at the market offering program, respectively. We may sell shares of our common stock and the marketable securities we own for liquidity. However, when we can effect such sales and the amount of shares we can sell depends on a variety of factors to be determined by us from time to time, including, among others, market conditions, the trading price and volume of our common stock and of the marketable securities we own. The market value of marketable securities we own may not represent the amount that could be realized in a sale of such securities due to various market factors, including prevailing market conditions and prices at the time of any sale. In addition, the market value of marketable securities we own may be significantly and adversely impacted by deteriorating global economic conditions and the recent disruptions to and volatility in the credit and financial markets in the United States and worldwide resulting from the recent pandemics, including the COVID-19 pandemic, geopolitical conflicts, rising inflation and interest rates, and other macroeconomic factors.

Cash Flows

Cash flows (used in) provided by operating activities

Net cash used in operating activities was $17.5 million for the six months ended June 30, 2023, which primarily reflects the loss from operations of $11.7 million plus the changes in operating assets and liabilities of $9.4 million. These items were offset by the non-cash expenses of $2.3 million for stock-based compensation and $0.3 million for depreciation and amortization. The unrealized loss on marketable securities, foreign currency remeasurement and deferred tax benefit had no effect on cash flows.

32 | Page

Net cash provided by operating activities was $14.8 million for the six months ended June 30, 2022, which primarily reflects the net changes in assets and liabilities of $22.5 million, plus the $2.7 million in non-cash expenses for stock-based compensation and depreciation and amortization, less the loss from operations of $10.6 million. The change in assets and liabilities was impacted by the receipt of the $50.0 million upfront payment under the Roche Agreement, and subsequent related payments to the IIA and Hadasit (see Note 14 (Commitments and Contingencies) to the condensed consolidated interim financial statements included in this report for additional information), partially offset by the accrual of the litigation settlement described in Note 14 (Commitments and Contingencies) to the condensed consolidated interim financial statements included in this report. The unrealized loss on marketable equity securities and foreign currency remeasurement had no effect on the cash flows.

Cash flows provided by (used in) investing activities

Cash provided by investing activities for the six months ended June 30, 2023 was $34.6 million and consisted of $47.7 million in U.S. Treasury securities which matured during the period, partially offset by $12.6 million used to purchase U.S. Treasury securities and $0.4 million used to purchase equipment.

Cash used by investing activities for the six months ended June 30, 2022 consisted of $0.1 million used to purchase equipment.

Cash flows provided by financing activities

Cash provided by financing activities for the three months ended June 30, 2023 was $5.6 million and primarily consisted of net proceeds from the sale of our common shares under our at the market offering program.

Cash provided by financing activities for the six months ended June 30, 2022 was $0.5 million and consisted of $0.4 million of proceeds from the exercise of employee stock options, $0.1 million of proceeds from the sale of our common shares under our at the market offering program, and $0.1 million of proceeds from the exercise of warrants to purchase shares of Cell Cure. These proceeds were partially offset by $0.1 million in financing costs.

Financial Obligations

Our financial obligations primarily consist of obligations to our licensors under license agreements, obligations related to grants received from government entities, including the IIA, obligations under vendor contracts to provide research services and other purchase commitments with suppliers.

Our obligations to licensors under license agreements and related to grants received from government entities require us to make future payments relating to sublicense fees, milestone payments, redemption fees, royalties and patent maintenance costs. Sublicense fees are payable to licensors or government entities when we sublicense underlying intellectual property to third parties; the fees are based on a percentage of the license fees we receive from sublicensees. Milestone payments, including those related to the Roche Agreement, are due to licensors or government entities upon future achievement of certain commercial, development and regulatory milestones. Redemption fees due to the IIA under the Innovation Law are due upon receipt of any milestone and royalties received under the Roche Agreement, see Note 14 (Commitment and Contingencies) for additional information. Royalties, including those related to royalties we may receive under the Roche Agreement, are payable to licensors or government entities based on a percentage of net sales of licensed products. Patent maintenance costs are payable to licensors as reimbursement for the cost of maintaining license patents. Due to the contingent nature of the payments, the amounts and timing of payments to licensors under our in-license agreements are uncertain and may fluctuate significantly from period to period. As of June 30, 2023, we have not included these commitments on our consolidated balance sheet because the achievement and timing of these events are not fixed and determinable.

33 | Page

As discussed above, we have received grants under the Innovation Law and are required to pay royalties to the IIA from the revenues generated from the sale of product candidates and related services developed, in whole or in part pursuant to, or as a result of, a research and development program funded by the IIA. Under the Innovation Law, we are also required to pay redemption fees to the IIA. To date, through a series of separate grants beginning in 2007, Cell Cure has received a total of $15.4 million from the IIA to support the OpRegen program. We are obligated to pay approximately 24.3% of any future payments received under the Roche Agreement to the IIA, up to an aggregate cap on all payments to IIA, such cap growing over time via interest accrual until paid in full, which was approximately $92.1 million as of June 30, 2023. Redemption fees due to the IIA under the Innovation Law are due upon receipt of any milestone payments and royalties received under the Roche Agreement. As of June 30, 2023, we have not included any future financial obligations due to the IIA under the Innovation Law in our consolidated balance sheet because the achievement and timing of the events that would require future payments to the IIA under the Innovation Law is not fixed and determinable. See Note 14 (Commitments and Contingencies) to our condensed consolidated interim financial statements included in this report for additional information.

Under the terms of the leases for the facilities from which Cell Cure and Lineage operate, a total of $3.8 million of rent payments will become due, of which $0.6 million will become due in 2023.

In the normal course of business, we enter into services agreements with contract research organizations, contract manufacturing organizations and other third parties. Generally, these agreements provide for termination upon notice, with specified amounts due upon termination based on the timing of termination and the terms of the agreement. The amounts and timing of payments under these agreements are uncertain and contingent upon the initiation and completion of the services to be provided.

Future Funding Requirements

At June 30, 2023, we had an accumulated deficit of approximately $373.0 million. We expect to continue to incur losses for at least the next several years. We expect that our operating expenses will continue to increase for the foreseeable future as we continue the development of, and seek regulatory approval for, our product candidates. As a result, we will need significant additional capital to fund our operations. Our determination as to when we will seek additional capital and the amount of additional capital that we will need will be based on our evaluation of the progress we make in our research and development programs, changes to the scope and focus of those programs, changes in grant funding for certain of those programs, and projection of future costs, revenues, and rates of expenditure. If we are unable to raise additional capital when and as needed, we may be required to delay, postpone, or cancel our clinical trials or limit the number of clinical trial sites.

We may seek to obtain the additional capital we may need through one or more equity offerings, debt financings or other third-party funding, including potential strategic alliances and licensing or collaboration agreements. We cannot assure that adequate additional capital will be available on favorable terms, if at all. The issuance of additional securities, whether equity or debt, or the possibility of such issuance, may cause the market price of our common shares to decline, and the issuance of additional equity securities could result in the dilution of the interests of our current shareholders. If we obtain additional capital through strategic alliances and licensing or collaboration agreements, we may be required to relinquish rights to our intellectual property, our product candidates or otherwise agree to terms unfavorable to us. The unavailability or inadequacy of additional capital to meet future capital needs could force us to modify, curtail, delay, or suspend some or all aspects of our current planned operations. Our ability to raise additional capital may be adversely impacted by deteriorating global economic conditions and the disruptions to and volatility in the credit and financial markets in the United States and worldwide resulting from the recent pandemics, including the COVID-19 pandemic, the conflict in Ukraine, rising inflation and interest rates, and other macroeconomic factors.

We believe that our $45.9 million in cash, cash equivalents and marketable securities at June 30, 2023, provide sufficient liquidity to carry out our current planned operations through at least twelve months from the issuance date of our condensed consolidated interim financial statements included elsewhere in this report. We believe we will meet our longer-term expected future cash requirements and obligations with our current cash and cash equivalents, milestone and other payments we expect to receive under our collaboration agreements, and proceeds we receive from sales of our common shares under our at the market offering program.

Market risk

As filed, 146 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Under SEC rules and regulations, as a smaller reporting company, we are not required to provide the information required by this item.

34 | Page

Controls and procedures

As filed, 1,354 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Evaluation of Disclosure Controls and Procedures

It is management’s responsibility to establish and maintain adequate internal control over all financial reporting pursuant to Rule 13a-15 under the Exchange Act. Our management, including our Chief Executive Officer and our Chief Financial Officer, reviewed and evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this report. Following this review and evaluation, management collectively determined that our disclosure controls and procedures were effective as of the end of the period covered by this report to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act: (i) is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms; and (ii) is accumulated and communicated to management, including our chief executive officer and our chief financial officer, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting that occurred during the period covered by this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Risk factors

As filed, 794 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

An investment in our common shares involves a high degree of risk. You should carefully consider the risks and uncertainties described in the 2022 10-K, in addition to other information in this report, when evaluating our business and before deciding whether to purchase, hold or sell our common shares. Each of these risks and uncertainties, as well as additional risks and uncertainties not presently known to us or that we currently consider immaterial, could harm our business, financial condition, results of operations and/or growth prospects, as well as adversely affect the market price of our common shares, in which case you may lose all or part of your investment. There have been no material changes from the risk factors disclosed in Part I, Item 1A. Risk Factors in the 2022 10-K.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2023-06-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Cost of revenue3 months2023-04-01 to 2023-06-30$127.0kus-gaap:CostOfRevenue
Cost of revenue6 months2023-01-01 to 2023-06-30$246.0kus-gaap:CostOfRevenue
Gross profit3 months2023-04-01 to 2023-06-30$3.1mus-gaap:GrossProfit
Gross profit6 months2023-01-01 to 2023-06-30$5.4mus-gaap:GrossProfit
Research and development3 months2023-04-01 to 2023-06-30$3.9mus-gaap:ResearchAndDevelopmentExpense
Research and development6 months2023-01-01 to 2023-06-30$8.1mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2023-04-01 to 2023-06-30−$5.0mus-gaap:OperatingIncomeLoss
Operating income6 months2023-01-01 to 2023-06-30−$11.7mus-gaap:OperatingIncomeLoss
Net income3 months2023-04-01 to 2023-06-30−$5.2mus-gaap:NetIncomeLoss
Net income6 months2023-01-01 to 2023-06-30−$9.6mus-gaap:NetIncomeLoss
Diluted EPS3 months2023-04-01 to 2023-06-30−$0.03us-gaap:EarningsPerShareDiluted
Diluted EPS6 months2023-01-01 to 2023-06-30−$0.06us-gaap:EarningsPerShareDiluted
Basic EPS3 months2023-04-01 to 2023-06-30−$0.03us-gaap:EarningsPerShareBasic
Basic EPS6 months2023-01-01 to 2023-06-30−$0.06us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2023-04-01 to 2023-06-30170,592,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)6 months2023-01-01 to 2023-06-30170,361,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow6 months2023-01-01 to 2023-06-30−$17.5mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure6 months2023-01-01 to 2023-06-30$444.0kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2023-06-30$33.9mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2023-06-30$48.5mus-gaap:AssetsCurrent
Total assetsAt period end2023-06-30$111.7mus-gaap:Assets
Current liabilitiesAt period end2023-06-30$16.1mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2023-06-30$40.4mus-gaap:Liabilities
Shareholders' equityAt period end2023-06-30$72.7mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001493152-23-027552. Last ingested by Listed: Nov 13, 2026, 16:09 ET. Listed shows no prices and gives no investment advice.